Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on Nu Skin Enterprises on Friday, setting a price target of $72, which is approximately 77.91% above the present share price of $40.47.
Feinseth expects Nu Skin Enterprises to post earnings per share (EPS) of $1.18 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Nu Skin, with an average price target of $66.2.
The analysts price targets range from a high of $72 to a low of $59.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $704.06 million and a net profit of $85.38 million. The company's market cap is $2.03 billion.
According to TipRanks.com, Tigress Financial analyst Ivan Feinseth is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 68.60% success rate.
Nu Skin Enterprises, Inc. develops and distributes personal care products and nutritional supplements. The firm engages in the provision of beauty and wellness products and solutions. Its brands include Nu Skin and Pharmanex. The company was founded by Blake M. Roney, Sandra N. Tillotson, and Steven J. Lund in 1984 and is headquartered in Provo, UT.